Home  ›  What Are the Chances of a Mother With Ocular Myasthenia Gravis Giving It to Her Baby

What Are the Chances of a Mother With Ocular Myasthenia Gravis Giving It to Her Baby

Written By Sunday, March 13, 2022 Add Comment Edit

Open access peer-reviewed chapter

Maternal and Neonatal Outcome of Pregnancies with Autoimmune Myasthenia Gravis

Submitted: July 16th, 2018 Reviewed: Dec 6th, 2018 Published: January 24th, 2019

DOI: 10.5772/intechopen.83356

IntechOpen

IntechOpen Downloads

806

Full Affiliate Downloads on intechopen.com

Abstract

Myasthenia gravis (MG) is an autoimmune neuromuscular disease manifested past the weakness and fatigue in skeletal muscles of the face up and extremities. Transient neonatal myasthenia gravis is an uncommon type of MG affecting the newborns with mothers who suffer from the disorder or specific circulating autoantibodies. In most cases, the intensity of transient neonatal MG is not associated with the mothers' condition but rather with maternal antibiotic titers. The symptoms of transient neonatal MG are hypotonia, feeding difficulties, weak weep, facial diplegia, and breathing difficulties in the affected newborns. The affliction is connected to the passive transplacental transfer of anti-acetylcholine receptor antibodies (anti-AChR) or antimuscle-specific tyrosine kinase antibodies (anti-MuSK) from the affected mother to the baby. The postsynaptic neuromuscular junction is damaged by the circulation of autoimmune antibodies, and the antibodies directed against fetal AChR are responsible for the form of fetal onset. Monitoring of these newborns is necessary in the first 7 days upon nascency, since during this period of life, TNM symptoms can be detected, specially on the second twenty-four hours. In pregnancy period, myasthenia gravis symptoms may vary and they frequently worsen, sometimes leading to premature delivery.

Keywords

  • neonates
  • pregnancy
  • autoimmune myasthenia gravis

i. Introduction

Myasthenia gravis (MG) is a chronic progressive disease which is manifested in weakness and tiredness of skeletal muscles equally most typical symptoms. Neuromuscular transmission defects are responsible for MG onset [1].

The expression "myasthenia gravis" is of Latin origin, where "myasthenia" means "musculus weakness" and "gravis" ways "serious" or "heavy." The first report on MG was recorded in 1672 past Thomas Willis (1621–1675), a doctor from England whose main surface area of research was the nervous system [two].

Although patients suffering from myasthenia gravis exercise not feel any changes in the nervous and muscular systems, this disease causes a disorder in the transmission of the impulse from the nerve to the muscle, resulting in musculus weakness which is a typical symptom of neurological diseases. 1 of the almost recognizable signals of this illness is the fluctuating weakness in the eyes, bulbar, limbs, and respiratory muscles [three, four].

MG can exist defined as a relatively rare autoimmune disorder, affecting approximately 2 out of every 100,000 people, and can develop at any age. In patients affected past MG, antibodies are formed confronting acetylcholine nicotinic postsynaptic receptors at the neuromuscular junction of skeletal muscles which leads to progressive skeletal muscle weakness [5]. Myasthenia gravis usually affects female person population at the age ranging from 18 to 25, whereas male population is affected by this disease afterward in life, at the historic period ranging from lx to lxxx [6].

Depending on the affected skeletal muscle groups, myasthenia gravis is categorized into several classes:

  • Class I: But ocular muscles are weakened with possible weakness of centre closure, while other muscles remain unaffected.

  • Class II: Mild weakness of any muscle group is possible as well as ocular muscle weakness of whatsoever degree.

  • Class IIa: Near commonly causes weakness in limb and axial muscles; occurrence of oropharyngeal muscle weakness is also possible.

  • Class IIb: Usually affects either oropharyngeal or respiratory muscles, but it can affect both muscle groups also; limb and/or centric muscles tin can besides be involved.

  • Form III: Mild weakness of any muscle group is possible also as ocular musculus weakness of any caste.

  • Class IIIa: Most commonly causes weakness in limb and axial muscles; occurrence of oropharyngeal muscle weakness is also possible.

  • Grade IIIb: Usually affects either oropharyngeal or respiratory muscles, but it tin affect both muscle groups as well; limb and/or centric muscles can besides be involved.

  • Class IV: Severe weakness of any muscle group is possible equally well as ocular muscle weakness of any degree.

  • Class IVa: Most commonly causes weakness in limb and centric muscles; occurrence of oropharyngeal muscle weakness is as well possible

  • Class IVb: Usually affects either oropharyngeal or respiratory muscles, simply it can bear upon both musculus groups equally well; limb and/or axial muscles can as well be involved; application of a feeding tube without intubation.

  • Class 5: Characterized by the necessity of intubation, with or without mechanical ventilation, with the exception of cases of its application in routine postoperative management [7].

Advertizing

2. Myasthenia gravis during pregnancy

Myasthenia gravis can bear on the courses of pregnancy and delivery, and it also presents a risk factor for the neonates [8]. On the other mitt, pregnancy can intensify the symptoms of myasthenia which can lead to complications during pregnancy and require a modified handling. Attention should be paid to ensure an optimal treatment and drug rubber before formulation. Myasthenia gravis tin can exist transferred to neonates. However, neonatal myasthenia gravis is a treatable and transient disease [nine]. MG is relatively frequent in the reproductive flow of ane/10,000 to 1/50,000 [10].

The clinical course of MG can exist altered unpredictably, and in various ways by pregnancy and the previous pregnancy, experiences are non a reliable source of information on the possible clinical course of subsequent pregnancies [11, 12].

In pregnancy, respiratory function of the lungs is compromised for two reasons. Hypoventilation caused by respiratory muscle weakness, on the one side, and diaphragm elevation caused past fetus growth on the other side lead to the reduction of the lung capacity [13].

MG symptoms tin be worsened by puerperal respiratory and urinary tract infections; in social club to avoid further complications, a prompt diagnosis and adequate antibiotic handling of these infections is necessary during pregnancy [14].

It should exist taken into consideration that the selected groups of antibiotics—for example, fluoroquinolones (such as moxifloxacin and ciprofloxacin), macrolides (such as azithromycin and erythromycin), and aminoglycosides (such as streptomycin and gentamicin)—tin can aggravate muscle weakness caused past MG; therefore, these types of antibiotics should be avoided [fifteen].

During pregnancy therapy administration has to exist based on private conditions and symptoms regarding the groups of muscles afflicted by MG in each patient, bearing in mind the possible side furnishings and consequences on the fetus [16].

For the symptomatic treatment of myasthenia gravis in the period of pregnancy, acetylcholinesterase inhibitors can be chosen. In virtually cases of MG during pregnancy, immunosuppressant corticosteroids are effective and hence should be selected in accord with the symptoms in specific cases of MG [17].

Occurrence of premature membrane rupture and preterm delivery were also reported in cases when patients were treated with high doses of corticosteroids. In that location are records on temporary increase of MG symptom severity triggered by the introduction of corticosteroid therapy. Although the introduction of immunosuppressive drugs should exist avoided earlier and during pregnancy, therapy reduction or discontinuation bears the chance of triggering a myasthenic crisis or exacerbation in pregnant myasthenic women. In order to control the teratogenic take a chance to the fetus, immunosuppressive drug dosages have to be advisedly balanced and individualized [eighteen].

On the other manus, recent reports suggest that azathioprine (AZA) therapy has shown to exist successful in treatments of MG during pregnancy and breastfeeding periods. Even though AZA is absorbed through the placenta, its negative effects on the fetus are relatively pocket-sized since the fetal liver is immature and lacks the enzyme responsible for the conversion of AZA into its active metabolites. Cyclosporine A treatment is not considered to be harmful during the period of pregnancy and breastfeeding, but information technology can as well trigger prematurity, spontaneous abortions, and insufficient birth weight at birth. Another drug, mycophenolate mofetil (MMF), is thought to be teratogenic, causing a clinical syndrome which includes hypoplastic nails, shortened fifth fingers, oral crack, microtia, diaphragmatic hernia, and micrognathia [19].

MG rarely affects the first stage of commitment, mostly because in this stage smooth muscles are involved. Notwithstanding, in the 2d phase, the mother tin can experience fatigue due to the involvement the voluntary striated muscles [20].

In this phase of delivery, mothers oft feel exhausted, which may involve myasthenic crunch; therefore, the obstetrician needs to be ready for an assisted vaginal delivery if required (e.thousand., performing vacuum extraction or using forceps) [21].

Since MG patients are peculiarly sensitive to a number of anesthetics, an anesthesiologist should be consulted at the beginning of the pregnancy. Both in vaginal and in surgical deliveries, epidural anesthesia not exceeding the 10th thoracic vertebra level is advisable in club to ensure an adequate analgesia. While amide-type local coldhearted agents (such as lidocaine, mepivacaine, and bupivacaine) take no impact on myasthenia, ester-blazon drugs (e.g., benzocaine, tetracaine, and procaine) are not the drug of selection because of the risk of aggravation of the existing myasthenia. Nonsteroidal anti-inflammatory medications (e.one thousand., ketorolac tromethamine) and paracetamol (acetaminophen) may be included to ease postpartum or postoperative pain, while narcotic analgesic agents that can contribute to respiratory depression are to be avoided [22].

Although anti-acetylcholine therapy can be used safely by nursing mothers suffering from MG, it may exacerbate symptoms of transient neonatal myasthenia gravis (TNMG), since anti-acetylcholine receptor antibodies (AChR-Ab) are contained in breast milk [23, 24].

Glucocorticoids and AZA are too not contraindicated in myasthenic mothers, only a liver function test must be performed, and complete blood count must exist monitored in the newborns breastfed by myasthenic mothers. However, in breastfeeding mothers with MG, mycophenolate mofetil is contraindicated [23].

Taking intendance of the newborn tin can be particularly strenuous for myasthenic mothers due to the lack of sleep at dark and constant daily caring for the baby. These extreme efforts may worsen the clinical symptoms of MG. In cases where immunosuppressive therapy has to be initiated or restarted afterwards giving birth, contraceptive counseling is strongly recommended. A carefully chosen contraceptive has to be prescribed a minimum of 1 month prior to the initiation of immunosuppressive therapy, and it should non be discontinued six months prior to a new pregnancy. A circadian withdrawal of oral contraceptives has been reported to initiate worsening of MG symptoms. In such cases, continuous hormonal contraception or an intrauterine device is more than preferable [25].

Advertisement

3. Newborns by myasthenic mothers

Neonatal MG is typically triggered by an autoactivation of the immune organization. The causative factor is not known, just the disorder may take a genetic defect, leading to congenital MG, or placental manual of maternal antibodies, resulting in transient neonatal MG. TNM is a temporary status caused by transplacental circulation of mothers' antibodies. It develops in x–twenty% cases of infants with myasthenic mothers, due to transplacental circulation of mothers' antibodies [26, 27].

In these infants general muscle weakness is noticeable together with deficient suck, languor, and breathing difficulty until the fourth day upon nascency. These symptoms are considered to be the consequence of transplacental transfer of antibodies. However, this causative effect is somewhat unclear, since a shut correlation has neither been found between the severity of MG in mothers and beingness of neonatal myasthenia nor between neonatal myasthenia gravis and maternal anti-AChR antibiotic titers. The correlation might exist explained past the protective role of alpha-fetoprotein in neonatal myasthenia gravis, every bit alpha-fetoprotein has been proven to inhibit the bounden of myasthenia gravis antibody to its receptor [28, 29].

Premature delivery occurs in approximately 35% of cases of mothers. The most common fetal abnormalities are pulmonary hypoplasia and arthrogryposis. Death from malformations attributable to myasthenia gravis has also been reported [thirty].

Although TNMG tin potentially be a life-threatening status, it can accept excellent prognosis if it is timely identified and properly treated [31].

Transient neonatal myasthenia gravis (TNMG) is a rare form of MG which affects the infants whose mothers take the disorder or specific circulating autoantibodies [32].

In that location are cases in which the mother is asymptomatic. The level of severity is not necessarily continued with the mother'southward condition but rather with maternal antibody titers. The onset is typically shown immediately later birth. The recognizable symptoms in infants affected by TNMG are hypotonia, feeding difficulties, weak cry, facial diplegia, and respiratory distress in the afflicted neonates. Most commonly, these symptoms recede gradually with the decrease in maternally derived antibodies. The risk of this disorder continues for the subsequent births. The verbal hazard factors for the condition are yet to be identified. If treated promptly, the symptoms resolve within two months upon birth [33, 34].

TNMG is connected to the passive transplacental transfer of anti-acetylcholine receptor antibodies (anti-AChR) or anti-muscle-specific tyrosine kinase antibodies (anti-MuSK) from the affected mother to the baby. The postsynaptic neuromuscular junction is damaged by the apportionment of autoimmune antibodies, and the antibodies directed confronting fetal AChR are responsible for the course of fetal onset [35].

The pathogenic role of acetylcholine receptor (AChR) antibodies has non been precisely determined. Despite the fact that passive-transfer acetylcholine receptor (AChR) antibodies are identified in nearly of these neonates, simply a small pct of infants develop the symptoms. A biological marker for prenatal detection of this group of neonates has not been identified still, but recent reports suggest that HLA typing can be used successfully for this purpose. Final diagnosis can be given when the therapy of acetylcholinesterase agents temporarily improves the neuromuscular transmission disorder. Serum AChR antibody titers behave in the same way every bit the maternal pattern.

Anticholinesterase agents and supportive management before breastfeeding are required in approximately lxxx% of cases. The symptoms disappear spontaneously in most cases [27, 36, 37].

Ad

iv. Conclusion

Newborns of mothers with MG manifest clinical features of TNM relative to the phase of the mothers' disease and transplacental transfer of antibodies to acetylcholine receptors throughout the placenta. These newborns need to be monitored until their 7th 24-hour interval of life, as TNM symptoms tin can exist visible from nascency to seven days of life, though most commonly on the second day of life. The clinical course of myasthenia gravis during pregnancy is variable, with a significant proportion of patients experiencing worsening of clinical symptoms and premature delivery.

Advertizement

Conflict of interest

No potential conflict of interest was reported by the authors.

References

  1. 1. Bourque PR, Breiner A. Myasthenia gravis. CMAJ. 2018;190:E1141
  2. 2. Drachman DB. Myasthenia gravis. The New England Journal of Medicine. 1994;330:1797-1810
  3. 3. Grob D, Brunner North, Namba T, Pagala M. Lifetime course of myasthenia gravis. Musculus & Nerve. 2008;37:141-149
  4. iv. Khanna Due south, Liao K, Kaminski HJ, Tomsak RL, Joshi A, Leigh RJ. Revitalized ocular myasthenia: Insights from pseudo-intercellular ophthalmoplegia. Journal of Neurology. 2007;254:1569-1574
  5. five. Barber C. Diagnosis and direction of myasthenia gravis. Nursing Standard. 2017;31:42-47
  6. vi. Niks EH, Verrips A, Semmekrot BA, et al. A transient neonatal myasthenic syndrome with anti-musk antibodies. Neurology. 2008;seventy:1215-1216
  7. 7. Jaretzki A 3, Jaretzki A tertiary, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, et al. Myasthenia gravis: Recommendations for clinical research standards. Job force of the medical scientific informational board of the myasthenia gravis foundation of America. Neurology. 2000;55:sixteen-23
  8. 8. Pijnenborg JM, Hansen EC, Brölmann HA, Oei SG, Andriessen P, Dellemijn PL. A severe instance of myasthenia gravis during pregnancy. Gynecologic and Obstetric Investigation. 2000;50:142-143
  9. 9. Hamel J, Ciafaloni East. An update: Myasthenia gravis and pregnancy. Neurologic Clinics. 2018;36:355-365
  10. 10. Roth CK, Dent S, McDevitt K. Myasthenia gravis in pregnancy. Nursing for Women's Wellness. 2015;19:248-252
  11. eleven. Wenninger S, Schoser B. Myasthenia gravis: Current status of antibody diagnostics and aspects on refractory myasthenia gravis. Fortschritte der Neurologie-Psychiatrie. 2018;86:551-558
  12. 12. Djelmis J, Sostarko Yard, Mayer D, Ivanisevic M. Myasthenia gravis in pregnancy: Report on 69 cases. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2002;104:21-25
  13. xiii. Plauché WC. Myasthenia gravis in mothers and their newborns. Clinical Obstetrics and Gynecology. 1991;34:82-99
  14. fourteen. Van Bambeke F, Harms JM, Van Laethem Y, Tulkens PM. Ketolides: Pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opinion on Pharmacotherapy. 2008;ix:267-283
  15. xv. Elsais A, Popperud Thursday, Melien Ø, Kerty East. Drugs that may trigger or exacerbate myasthenia gravis. Tidsskrift for den Norske Lægeforening. 2013;133:296-299
  16. 16. Ciafaloni East, Massey JM. The direction of myasthenia gravis in pregnancy. Seminars in Neurology. 2004;24:95-100
  17. 17. Stafford IP, Dildy GA. Myasthenia gravis and pregnancy. Clinical Obstetrics and Gynecology. 2005;48:48-56
  18. 18. Imai T, Utsugisawa Thou, Murai H, Tsuda East, Nagane Y, Suzuki Y, et al. Oral corticosteroid dosing regimen and long-term prognosis in generalized myasthenia gravis: A multicenter cross-exclusive study in Nippon. Journal of Neurology, Neurosurgery, and Psychiatry. 2018;89:513-517
  19. 19. Norwood F, Dhanjal M, Loma M, James N, Jungbluth H, Kyle P, et al. Myasthenia in pregnancy: Best practice guidelines from a U.K. multispecialty working grouping. Periodical of Neurology, Neurosurgery, and Psychiatry. 2014;85:538-543
  20. 20. Ducci RD, Lorenzoni PJ, Kay CS, Werneck LC, Scola RH. Clinical follow-up of pregnancy in myasthenia gravis patients. Neuromuscular Disorders. 2017;27:352-357
  21. 21. Massey JM, De Jesus-Acosta C. Pregnancy and myasthenia gravis. Continuum. 2014;20:11527
  22. 22. Hassan A, Yasawy ZM. Myasthaenia gravis: Clinical management issues before, during and after pregnancy. Sultan Qaboos University Medical Journal. 2017;17:e259-e267
  23. 23. Varner M. Myasthenia gravis and pregnancy. Clinical Obstetrics and Gynecology. 2013;56:372-381
  24. 24. Papazian O. Transient neonatal myasthenia gravis. Journal of Kid Neurology. 1992;7:135-141
  25. 25. Khadilkar SV, Sahni AO, Patil SG. Myasthenia gravis. The Journal of the Clan of Physicians of Republic of india. 2004;52:897-904
  26. 26. Cheng I, Lin CH, Lin MI, Lee JS, Chiu HC, Mu SC. Outcome of myasthenia gravis mothers and their infants. Acta Paediatrica Taiwanica. 2007;48:141-145
  27. 27. Oger J, Frykman H. An update on laboratory diagnosis in myasthenia gravis. Clinica Chimica Acta. 2015;449:43-48
  28. 28. Saint-Faust M, Perelman Due south, Dupont D, Velin P, Chatel M. Transient neonatal myasthenia gravis revealing a myasthenia gravis and a systemic lupus erythematosus in the female parent: Case report and review of the literature. American Periodical of Perinatology. 2010;27:107-110
  29. 29. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: Identifying adventure factors, optimising care. European Journal of Neurology. 2007;14:38-43
  30. 30. Maddison P. Myasthenia gravis and pregnancy: Pressing time for best practice guidelines. Periodical of Neurology, Neurosurgery, and Psychiatry. 2014;85:477
  31. 31. Qi QW, Wang D, Liu JT, Bian XM. Management of pregnancy with myasthenia gravis: 7 cases report. Zhonghua Fu Chan Ke Za Zhi. 2012;47:241-244
  32. 32. Gajda A, Szabó H, Gergev Grand, Karcagi Five, Szabó N, Endreffy E, et al. Built myasthenic syndromes and transient myasthenia gravis. Ideggyógyászati Szemle. 2013;66:200-203
  33. 33. Edmundson C, Guidon AC. Neuromuscular disorders in pregnancy. Seminars in Neurology. 2017;37:643-652
  34. 34. Eymard B, Morel East, Dulac O, Moutard-Codou ML, Jeannot E, Harpey JP, et al. Myasthenia and pregnancy: A clinical and immunologic study of 42 cases (21 neonatal myasthenia cases). Revue Neurologique. 1989;145:696-701
  35. 35. Eymard B. Antibodies in myasthenia gravis. Revista de Neurologia. 2009;165:137-143
  36. 36. D'Amico A, Bertini E, Bianco F, et al. Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report. Neuromuscular Disorders. 2012;22:546-548
  37. 37. Ramirez C, de Seze J, Delrieu O, Stojkovic T, Delalande Southward, Fourrier F, et al. Myasthenia gravis and pregnancy: Clinical course and management of delivery and the postpartum phase. Revista de Neurologia. 2006;162:330-338

Written By

Miljana Z. Jovandaric and Svetlana J. Milenkovic

Submitted: July 16th, 2018 Reviewed: December 6th, 2018 Published: January 24th, 2019

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed nether the terms of the Creative Eatables Attribution three.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

westmorelandropened.blogspot.com

Source: https://www.intechopen.com/chapters/65042

0 Response to "What Are the Chances of a Mother With Ocular Myasthenia Gravis Giving It to Her Baby"

Post a Comment

Subscribe to: Post Comments (Atom)

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel